Duarte-Vázquez Miguel Ángel, Gómez-Solís María Antonieta, Gómez-Cansino Rocio, Reyes-Esparza Jorge, Jorge Luis Rosado and Rodríguez-Fragoso Lourdes
Background: The worldwide prevalence of Type 2 diabetes mellitus is associated with other conditions that trigger metabolic syndrome. Although several studies on the benefits of resveratrol have been carried out, few have assessed this drug in combination with metformin. Objectives: This study looks at the effects that combined metformin/resveratrol therapy has on body weight gain and liver and renal damage of db/db diabetic mice. It also addresses biochemical findings. Method: Diabetic mice were treated with resveratrol (20 mg/kg/day), metformin (150 mg/kg/day) and combined metformin/resveratrol therapy for 5 weeks. Histopathological tissue analyses and biochemical parameters (glucose, insulin, triglycerides and cholesterol), functional liver enzymes (AP, AST and GGT) and renal parameters (urea and uric acid) were examined. Results: Our data clearly showed that combined metformin/resveratrol treatment reduced obesity, glucose and triglyceride levels, as well as improving renal function and partially improving liver function in diabetic mice. Conclusion: The combined therapy may enhance remedial effects in diabetic patients as well as in other metabolic disorders, such as metabolic syndrome.
இந்தக் கட்டுரையைப் பகிரவும்
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 